KAREN RABIN to Drug Resistance, Neoplasm
This is a "connection" page, showing publications KAREN RABIN has written about Drug Resistance, Neoplasm.
Connection Strength
0.514
-
Personalized care of pediatric cancer patients. Nestle Nutr Workshop Ser Pediatr Program. 2008; 62:173-85; discussion 185-8.
Score: 0.210
-
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia. 2025 Mar; 39(3):555-567.
Score: 0.170
-
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med. 2018 12 03; 215(12):3094-3114.
Score: 0.111
-
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015 Oct; 62(10):1717-24.
Score: 0.022